drugset / Trial / NCT07710612
A Phase 2 Study of ABSK043 Combined With Osimertinib
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 2, open-Label study to evaluate the efficacy and safety of ABSK043 Combined with Osimertinib in participants with EGFR-Mutated locally advanced or metastatic Non-Small Cell Lung Cancer
Timeline
- Start
- 2026-08-31
- Primary completion
- 2029-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABSK043 | Small molecule | — | — |
| Background | Osimertinib | Small molecule | 80 mg | Oral |